B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases
CPT: Pharmacometrics & Systems Pharmacology · 2026
DOI: 10.1002/psp4.70151 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2026. Verfasst von Tomohisa Nakada und 1 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Technology Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan. Hauptthemen laut MEDLINE: Rituximab, B-Lymphocytes, Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Rituximab (RTX), an anti‐CD20 monoclonal antibody, has been used to treat autoimmune diseases such as rheumatoid arthritis (RA). However, variability in therapeutic response to RTX remains a challenge. Here, a systems model is developed to mimic B cell differentiation leading to antibody‐secreting cells (ASCs), including plasmablasts (PBs) and plasma cells (PCs). The model features the localization of B cell subsets in the bone marrow and secondary lymphoid organs and incorporates the internalization process of the CD20–RTX complex. To reproduce clinical data from patients with RA receiving RTX and glucocorticoids, pharmacokinetic models for the drugs were built and respective pharmacodynamic profiles of CD19 + and CD20 + cells and PBs were well captured by optimizing model parameters, which were estimated with good precision. As ASCs are the primary source of pathogenic autoantibodies in RA, the extent and duration of ASC depletion were hypothesized as drivers of therapeutic response to RTX. Global sensitivity analyses identified the CD20–RTX binding affinity and elimination rate constant (i.e., Fcγ‐mediated degradation, internalization) as major determinants of both CD19 + cells and ASCs. The influence of baseline PBs and PCs on ASCs was also suggested, providing potential mechanisms underlying responder and non‐responder variability. The model accurately reproduced the temporal changes in CD19 + cells after combination treatment with RTX and glucocorticoids suggesting successful model validation. This study provides a mechanistic framework and insights into key drivers of responses to CD20‐depletion treatment using B cell dynamics as an indirect biomarker of clinical endpoints, which might ultimately improve therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Technology Laboratories, Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
- Division of Pharmacokinetics-Pharmacodynamics and Systems Pharmacology, Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.
- Enhanced Pharmacodynamics, LLC, Buffalo, New York, USA.
ORCID-Profile: Tomohisa Nakada, Donald E Mager
Zitieren
APA
Nakada, T., & Mager, D. E. (2026). B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70151
Vancouver
Nakada T, Mager DE. B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases. CPT: Pharmacometrics & Systems Pharmacology. 2026. doi:10.1002/psp4.70151
BibTeX
@article{Nakada2026,
author = {Nakada, Tomohisa and Mager, Donald E},
title = {B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
doi = {10.1002/psp4.70151}
}
EUVIMED